Sangamo Therapeutics Management
Management criteria checks 2/4
Sangamo Therapeutics' CEO is Sandy Macrae, appointed in Jun 2016, has a tenure of 7.92 years. total yearly compensation is $2.39M, comprised of 29.9% salary and 70.1% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $180.33K. The average tenure of the management team and the board of directors is 1.9 years and 4.5 years respectively.
Key information
Sandy Macrae
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 29.9% |
| CEO tenure | 7.9yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.9yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Mar 23
Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Mar 16We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate
Mar 09Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet
Feb 02Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Dec 04Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?
Sep 11Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
Aug 15Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S
Aug 08Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be
May 30Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)
May 13Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky
Apr 11We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully
Dec 20Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy
Sep 22Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Sep 18Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead
Aug 31Sangamo Therapeutics: Cheap, But Justifiably So
Aug 09Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
May 08Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?
Apr 11Sangamo Therapeutics: Lost In Transition From Lab To Clinic
Feb 24Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans?
Jan 10Sangamo Therapeutics: Remaining Bullish Ahead ASH Data In December
Dec 03We're Interested To See How Sangamo Therapeutics (NASDAQ:SGMO) Uses Its Cash Hoard To Grow
Sep 22Sangamo Therapeutics: Finding An Opportunity To Reload
Aug 21Sangamo's Hemophilia A Treatment: An Assessment
May 31We Think Some Shareholders May Hesitate To Increase Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation
May 19Sangamo Therapeutics Q1 2021 Earnings Preview
May 03Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Feb 27What Type Of Shareholders Own The Most Number of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares?
Feb 12
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$716k | -US$258m |
| Sep 30 2023 | n/a | n/a | -US$250m |
| Jun 30 2023 | n/a | n/a | -US$199m |
| Mar 31 2023 | n/a | n/a | -US$127m |
| Dec 31 2022 | US$5m | US$709k | -US$192m |
| Sep 30 2022 | n/a | n/a | -US$178m |
| Jun 30 2022 | n/a | n/a | -US$172m |
| Mar 31 2022 | n/a | n/a | -US$176m |
| Dec 31 2021 | US$5m | US$689k | -US$178m |
| Sep 30 2021 | n/a | n/a | -US$181m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$124m |
| Dec 31 2020 | US$4m | US$682k | -US$121m |
| Sep 30 2020 | n/a | n/a | -US$76m |
| Jun 30 2020 | n/a | n/a | -US$102m |
| Mar 31 2020 | n/a | n/a | -US$96m |
| Dec 31 2019 | US$4m | US$662k | -US$95m |
| Sep 30 2019 | n/a | n/a | -US$118m |
| Jun 30 2019 | n/a | n/a | -US$104m |
| Mar 31 2019 | n/a | n/a | -US$90m |
| Dec 31 2018 | US$4m | US$636k | -US$68m |
| Sep 30 2018 | n/a | n/a | -US$63m |
| Jun 30 2018 | n/a | n/a | -US$62m |
| Mar 31 2018 | n/a | n/a | -US$58m |
| Dec 31 2017 | US$2m | US$612k | -US$55m |
Compensation vs Market: Sandy's total compensation ($USD2.39M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Sandy's compensation has been consistent with company performance over the past year.
CEO
Sandy Macrae (60 yo)
7.9yrs
Tenure
US$2,392,272
Compensation
Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch B, Ph D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019.Dr. Macrae has been the Chief Executive Office...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 7.9yrs | US$2.39m | 0.17% $ 180.3k | |
| Senior VP | 4.9yrs | US$1.06m | 0.031% $ 33.0k | |
| Senior VP & Chief Development Officer | 5.3yrs | US$1.03m | 0.037% $ 39.5k | |
| Head of Research | less than a year | no data | 0.013% $ 13.7k | |
| Head of Technology | less than a year | no data | no data | |
| Head of Corporate Communications & Investor Relations Officer | no data | no data | no data | |
| Senior VP | 2.8yrs | no data | 0.036% $ 38.1k | |
| Head of Technical Operations | less than a year | no data | no data | |
| Head of Business Development & Alliance Management | less than a year | no data | no data | |
| Scientist II - Discovery & Translational Research | no data | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data |
1.9yrs
Average Tenure
54yo
Average Age
Experienced Management: SGMO's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 7.9yrs | US$2.39m | 0.17% $ 180.3k | |
| Independent Chairwoman of the Board | 9.9yrs | US$99.28k | 0.023% $ 25.1k | |
| Independent Director | 7.9yrs | US$80.53k | 0.017% $ 18.4k | |
| Member of Scientific Advisory Board | 4.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.5yrs | no data | no data | |
| Independent Director | 5.9yrs | US$76.78k | 0.018% $ 19.7k | |
| Member of Scientific Advisory Board | 4.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.5yrs | no data | no data |
4.5yrs
Average Tenure
65.5yo
Average Age
Experienced Board: SGMO's board of directors are considered experienced (4.5 years average tenure).